- Home
- NRIX vs ACP Comparison
NRIX vs ACP Comparison
Compare NRIX & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- ACP
- Stock Information
- Founded
- NRIX 2009
- ACP 2010
- Country
- NRIX United States
- ACP United States
- Employees
- NRIX N/A
- ACP N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- NRIX Health Care
- ACP Finance
- Exchange
- NRIX Nasdaq
- ACP Nasdaq
- Market Cap
- NRIX 908.0M
- ACP 737.8M
- IPO Year
- NRIX 2020
- ACP N/A
- Fundamental
- Price
- NRIX $11.64
- ACP $5.88
- Analyst Decision
- NRIX Strong Buy
- ACP
- Analyst Count
- NRIX 16
- ACP 0
- Target Price
- NRIX $30.44
- ACP N/A
- AVG Volume (30 Days)
- NRIX 857.7K
- ACP 337.9K
- Earning Date
- NRIX 07-10-2025
- ACP 01-01-0001
- Dividend Yield
- NRIX N/A
- ACP 17.79%
- EPS Growth
- NRIX N/A
- ACP N/A
- EPS
- NRIX N/A
- ACP N/A
- Revenue
- NRIX $56,417,000.00
- ACP N/A
- Revenue This Year
- NRIX $16.69
- ACP N/A
- Revenue Next Year
- NRIX N/A
- ACP N/A
- P/E Ratio
- NRIX N/A
- ACP N/A
- Revenue Growth
- NRIX N/A
- ACP N/A
- 52 Week Low
- NRIX $8.18
- ACP $5.55
- 52 Week High
- NRIX $29.56
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- NRIX 54.44
- ACP 54.62
- Support Level
- NRIX $11.17
- ACP $5.73
- Resistance Level
- NRIX $11.99
- ACP $5.93
- Average True Range (ATR)
- NRIX 0.58
- ACP 0.04
- MACD
- NRIX -0.07
- ACP -0.01
- Stochastic Oscillator
- NRIX 37.50
- ACP 70.00
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.